Prognostic Significance of BCL-6 Protein and KI-67 Monoclonal Antibody in Large Cell B-lymphoma Treated with Polichemiotherapy with or without Addition of Rituximab

Authors

  • Aida Arnautovic Department of Hematology, Clinic for Oncology, Haemathology and Radiotherapeutics, University Clinical Center Tuzla
  • Elmir Cickusic Department of Pathology University Clinical Center Tuzla
  • Samira Hasic Department of Hematology, Clinic for Oncology, Haemathology and Radiotherapeutics, University Clinical Center Tuzla
  • Haris Sahovic Department of Hematology, Clinic for Oncology, Haemathology and Radiotherapeutics, University Clinical Center Tuzla
  • Predrag Jovanovic Department of Gastroenterology and Hepatology, University Clinical Center Tuzla
  • Svetlana Jovic Department of Blood Transfusion, University Clinical Center Tuzla

DOI:

https://doi.org/10.5457/ams.v41i1.165

Keywords:

diffuse large cell lymphoma, bcl6, Ki-67

Abstract

Introduction: Lymphomas are malignant neoplasms of lymphoid tissue characterized by heterogenecity in pathology and clinical symptomatology. Diffuse large cell lymphoma (DLCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for almost 35-40% of all cases of NHL. Aim: To analyse the expression of Ki-67 i bcl-6, in large cell lymphoma tissue, treated with CHOP and CHOP+R protocol, and to evaluate the level of therapeutic response and the duration of progression free survival of the disease in patients with diffuse large cell lymphoma, treated by therapeutic protocols CHOP and CHOP+R. Methods: For analysis of both Ki-67 and bcl-6 we used criterion for positivity of >10% expression in lymphoid tissue. Results: The median of precentual expression of bcl-6 in total sample was 15,5% with interquartile range of 5,5% and 54,5%, and with minimum of 0% and maximum of 99%. Considering the criterion of bcl-6 positivity with 10% positive lymphoma cells, in total sample there was 29/50 (48,3%) bcl-6 positive cells. Comparing the two different treatments, there was no difference in level of bcl-6 expression. (Mann-Whitney; U=398; p=0,44). There was also no difference in incidence of bcl-6 positive patients (considering the criterion of >10% expression) between two types of treatment (X2=0,60; df=1; p=0,44). The median value of procentual Ki-67 expression in total sample was 59% with interquartile range of 33% to 74%, and minimum from 11% to 96%. All the patients were Ki-67 positive, considering the criterion of >10% expression in lymphoid tissue. Compared within two therapeutic groups, there was no difference in level of Ki-67 expression (Mann-Whitney; U=403,5; p=0,49). Separate Cox analiysis for both treated groups of patients was made to evaluate the separate prognostic influence of bcl-6 and Ki-67 on the duration of progression free survival of the disease. In the group of patients treated with CHOP protocol niether bcl-6 (OR=0,99; %CI=0,96-1,02; p=0,44) nor Ki-67 (OR=0,99; %CI=0,97-1,02; p=0,60) showed significant influence on duration of progression free survival of the disease. In the group of patients treated with CHOP+R protocol, there was also no significant influence of bcl-6 (OR=0,93; %CI=0,82-1,07; p=0,32) and Ki-67 (OR=1,02; %CI=0,97-1,08; p=0,42) on duration of progression free survival. Conclusions: These data suggest that Ki-67 and bcl-6 expression in tumor tissue can not be used as indicators for the level of therapy response and progression-free period in large cell B-lymphoma treated with polichemiotherapy with or without addition of Rituximab.

Downloads

Published

2012-10-30

Issue

Vol. 41 No. 1 (2012)

Section

Original papers

License

Copyright transfer

The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.